On October 22, 2024, Shanghai UnionClin Co., Ltd. (hereinafter referred to as UnionClin) was conducting "A Phase 1b/2a Clinical Study of JJH201601 Liposome Injection for the Treatment of Patients with Advanced Pancreatic Cancer, Biliary Tract Cancer, and Hepatocellular Carcinoma" at Nanjing Tianyinshan Hospital, and the first subject was successfully enrolled and treated.

This project was officially initiated on October 16, 2024 at Nanjing Tianyinshan Hospital. This is the first formal collaboration project between UnionClin and Nanjing Tianyinshan Hospital and also the second Phase I clinical study initiated by Nanjing Tianyinshan Hospital. The kick-off meeting was jointly presided over by Professor Shukui Qin, a well-known oncology clinical research expert at home and abroad, and Director Yingxia Chen, head of the Institutional Office. Chen Xun, Deputy Director of the Department of Hepatobiliary and Pancreatic Oncology at Nanjing Tianyinshan Hospital, the sponsor, the responsible person of UnionClin and project research staff, personnel of relevant departments, and clinical study management personnel attended the meeting.

Pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma are highly malignant, and there is a lack of standard therapeutic drugs for subsequent treatments, so more new drugs are required urgently. Relying on rich clinical resources, UnionClin precisely matched the sponsor's needs and combined with the product characteristics, and the medical and operations teams actively assisted the PI in quickly discussing and formulating the clinical development strategy for the product. They rapidly completed the clinical study protocol design, study site selection, site initiation, and other work at the SSU (site selection and start-up) stage, and completed the enrollment of the first subject one week after the kick-off meeting, so the FPI (first patient in) key milestone is achieved.

UnionClin team will uphold the mission of "accelerating clinical development of new drugs and seeking new life for thousands of patients", and continue contributing to this clinical research. Upholding a patient-centric approach and focusing on unmet clinical needs, we will further explore the efficacy and safety of this product in advanced pancreatic cancer, biliary tract cancer, and hepatocellular carcinoma, thereby accelerating the progress of new drug development.